Pharmaron H1 2026: Revenue RMB 7.60B, Up 17.92%; New Order Intake Grows Over 30%

CDMO services new orders jumped over 50% with segment revenue of RMB 1.88B (+32.78%); the company guides 15–20% full-year revenue growth. Revenue from the global top-20 pharma clients surged 31.95%.

Pharmaron (300759.SZ / 3759.HK) reported H1 2026 results on August 20: revenue of RMB 7.60B, up 17.92% YoY; net profit attributable of RMB 750M, up 6.96%; and adjusted non-IFRS net profit of RMB 909M, up 20.29%. Based on new-order and business trends, the company expects 15–20% full-year revenue growth.

During the period, Pharmaron reorganized into three platforms: Laboratory Services, CDMO Services and Clinical Research Services. CDMO led the way: revenue of RMB 1.88B, up 32.78% YoY, with gross margin of 25.72%, up 2.57 ppts. Its small-molecule CDMO covers 782 molecules or intermediates, including 45 process-validation/commercial-stage and 51 Phase III projects.

Laboratory Services delivered RMB 4.63B revenue (+13.72%, gross margin 40.89%), with biology accounting for over 60%; Clinical Research Services earned RMB 1.07B (+13.75%). Total new orders grew over 30% — CDMO services new orders up more than 50%, laboratory services up more than 20%.

Client mix keeps improving: 470+ new clients were added, and revenue from the global top-20 pharma companies reached RMB 1.54B, up 31.95%, or 20.29% of revenue. By region, North America contributed RMB 4.68B (61.55%) while mainland China grew 41.93% to RMB 1.38B. Headcount reached 27,316, with 11 operating entities in the UK and US. The company also completed an H-share placement in January, netting ~RMB 1.19B.